The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Enerzair Breezhaler indacaterol;glycopyrronium bromide;mometasone | Novartis Europharm Limited | Asthma | 🇪🇺 EU 2020-07-03 | Order → |
| Veklury remdesivir | Gilead Sciences Ireland UC | COVID-19 virus infection | 🇪🇺 EU 2020-07-03 | Order → |
| Zimbus Breezhaler indacaterol;glycopyrronium;mometasone furoate | Novartis Europharm Limited | Asthma | 🇪🇺 EU 2020-07-03 | Order → |
| Mvabea Ebola vaccine (MVA-BN-Filo [recombinant]) Exceptional circumstancesAdditional monitoring | Hemorrhagic Fever, Ebola | 🇪🇺 EU 2020-07-01 | Order → | |
| Zabdeno ebola vaccine (Ad26.ZEBOV-GP [recombinant]) Exceptional circumstancesAdditional monitoring | Hemorrhagic Fever, Ebola | 🇪🇺 EU 2020-07-01 | Order → | |
| Daurismo glasdegib Orphan | Pfizer Europe MA EEIG | Leukemia, Myeloid, Acute | 🇪🇺 EU 2020-06-26 | Order → |
| Fingolimod Accord fingolimod Generic | Accord Healthcare S.L.U. | Multiple Sclerosis, Relapsing-Remitting | 🇪🇺 EU 2020-06-25 | Order → |
| Insulin aspart Sanofi insulin aspart Biosimilar | Sanofi Winthrop Industrie | Diabetes Mellitus | 🇪🇺 EU 2020-06-25 | Order → |
| Reblozyl luspatercept OrphanAdditional monitoring | Bristol Myers Squibb Pharma EEIG | Anemia; Myelodysplastic Syndromes; beta-Thalassemia | 🇪🇺 EU 2020-06-25 | Order → |
| Byannli (previously Paliperidone Janssen-Cilag International) paliperidone | Schizophrenia | 🇪🇺 EU 2020-06-18 | Order → | |
| Atectura Breezhaler indacaterol;mometasone | Novartis Europharm Limited | Asthma | 🇪🇺 EU 2020-05-30 | Order → |
| Bemrist Breezhaler indacaterol;mometasone | Novartis Europharm Limited | Asthma | 🇪🇺 EU 2020-05-30 | Order → |
| Sarclisa isatuximab | Sanofi Winthrop Industrie | Multiple Myeloma | 🇪🇺 EU 2020-05-30 | Order → |
| Fluad Tetra influenza vaccine (surface antigen, inactivated, adjuvanted) | Seqirus Netherlands B.V. | Influenza, Human | 🇪🇺 EU 2020-05-20 | Order → |
| Nepexto etanercept Biosimilar | Biosimilar Collaborations Ireland Limited | Arthritis, Rheumatoid; Arthritis, Juvenile Rheumatoid; Arthritis, Psoriatic; Spondylarthropathies; Spondylitis, Ankylosing; Psoriasis | 🇪🇺 EU 2020-05-20 | Order → |
| Zeposia ozanimod | Bristol-Myers Squibb Pharma EEIG | Multiple Sclerosis, Relapsing-Remitting; Colitis, Ulcerative | 🇪🇺 EU 2020-05-20 | Order → |
| Zolgensma onasemnogene abeparvovec OrphanPRIMEATMP | Novartis Europharm Limited | Muscular Atrophy, Spinal | 🇪🇺 EU 2020-05-18 | Order → |
| Fetcroja cefiderocol | Shionogi B.V. | Gram-Negative Bacterial Infections | 🇪🇺 EU 2020-04-23 | Order → |
| Tigecycline Accord tigecycline Generic | Accord Healthcare S.L.U. | Soft Tissue Infections; Intraabdominal Infections; Bacterial Infections; Skin Diseases, Infectious | 🇪🇺 EU 2020-04-17 | Order → |
| Cinacalcet Accordpharma cinacalcet Generic | Accord Healthcare S.L.U. | Hyperparathyroidism | 🇪🇺 EU 2020-04-03 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.